The cornerstone of treatment is corticosteroid therapy. However, the current therapeutic strategy is not clearly defined. Objectives: The primary endpoint was relapse, defined as an increase of at least 1 point of the Extrapulmonary Organ Severity Tool ePOST score after initial improvement.
Secondary endpoints included therapeutic response, cortisone sparing and adverse events. Methods: We conducted a French multicenter retrospective study. Patients with definite or probable neurosarcoidosis histologically proven sarcoidosis and presence of a neurological localization were divided into 3 groups according to the treatment received: CYC group, infliximab IFX group and MTX group. The overall relapse-free survival rate was There was no statistical difference in therapeutic response between the 3 groups.
A significant decrease in corticosteroid therapy was observed in all 3 treatment groups, with no statistical difference between them. Conclusion: Our study shows that Infliximab and Methotrexate are two effective therapeutic options for relapse prevention in neurosarcoidosis. Today, Cyclophosphamide, the historic treatment for severe sarcoidosis, appears to be a third-line choice, given the risk of relapse and its tolerability profile. Neurosarcoidosis: clinical manifestations, investigation and treatment.
Practical Neurology. JAMA Neurology. JAMA Neurol. Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil. Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. Skip to main content. Log In More Log in via Institution. Log in via OpenAthens. Log in using your username and password For personal accounts OR managers of institutional accounts.
Forgot your log in details? Register a new account? Forgot your user name or password? Search for this keyword. Advanced search. Close More Main menu Archive. Log in via Institution. Email alerts. Article Text. Article menu. Scientific Abstracts. Gomez 1 , J.
